)
Visual
earnings real time
Celadon Pharmaceuticals
Celadon Pharmaceuticals (CEL) investor relations material
Celadon Pharmaceuticals has been delisted
Celadon Pharmaceuticals H1 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2024 earnings summary30 Sep, 2024
Executive summary
Entered strategic collaboration with Valeos Pharma A/S to license IP and genetics, accelerating EU supply and enabling earlier product delivery to European customers; Valeos to begin cultivation for Celadon’s customer in Q1 2025.
Completed 12 harvests from Phase 1 grow facility, with 16 harvests expected in 2024; Phase 2 construction and HVAC design finalized, though fit-out delayed due to funding issues.
Signed major sales contracts, including a 3-year deal worth up to £8.7m annually and a 5-year contract worth approximately £40.7m; UK contracts with potential annual revenue of £1.5m.
Supplied first product to US customer and continued UK sales, marking entry into the US market.
Raised £2.65m gross from equity raises during and after the period; £0.4m remains due from committed subscription; ongoing discussions for further debt facilities.
Financial highlights
Revenue for the six months ended 30 June 2024 was £63k, up from £8k in the prior year period.
Operating loss reduced to £2.3m (2023: £3.2m); loss before tax narrowed to £2.4m (2023: £4.4m), reflecting lower transaction costs and improved cultivation.
Gross profit of £350k (2023: £26k loss), reflecting improved cultivation and fair value adjustments; fair value of biological assets at 30 June 2024 was £129k to £338k.
Cash balance at 30 June 2024 was £16k, with £0.5m at 27 September 2024 after equity raises; inventory increased to £319k (2023: £24k).
Net assets at 30 June 2024 were £2.5m, down from £3.0m at 30 June 2023.
Outlook and guidance
Strategic partnership with Valeos expected to commence cultivation in Q1 2025, increasing annual capacity to ~4.5 tonnes and accelerating European supply.
Phase 2 facility to focus on UK and international markets as EU supply is accelerated via Valeos; completion delayed due to funding.
Available cash expected to finance working capital through December 2024; ongoing discussions for further debt facilities and equity raises.
Optimistic about medium- to long-term sector growth, especially as UK CBMP market develops.
Update on long-term debt facility discussions?
Expected yield increase from Valeos IP license?
Phase 2 facility's target market post-completion?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- LZ
Subscription focus, AI integration, and new DIFM products drive growth and margin gains. - OTP
Profit after tax reached HUF 826bn, with 24.9% ROE and strong capital and loan growth. - VNET
AI-driven wholesale IDC growth fueled revenue and profit surge; outlook and liquidity improved. - GMGI
Q3 revenue up 85% to $41M, with strong growth from acquisitions and platform expansion. - UPL
Q2 FY2025 saw strong volume growth and lower net debt, but margins declined on pricing pressure. - PFE
Q3 2024 revenue up 31–32% to $17.7B; guidance raised on strong oncology and vaccine growth. - MRK
Oncology and animal health drove 7% 2024 growth; 2025 outlook strong despite China vaccine headwinds. - VSCO
Q3 2024 net sales up 7% with improved margins, narrowed loss, and raised outlook. - EOAN
2024 results exceeded guidance, with €9bn EBITDA, record CapEx, and raised 2028 targets. - DALN
Adjusted operating loss improved to $0.7M as digital and agency growth offset print declines.
Celadon Pharmaceuticals
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage